Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY25 results · Jan–Mar 2025
Panacea Biotec reported revenue from operations of ₹132.53 crore (down 2.9% from Q4 FY24) and net loss of ₹1.99 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 132.53 | 136.46 | −2.9% | 163.49 | −18.9% |
| Other income | 8.59 | 10.81 | −20.5% | 3.62 | +137.3% |
| Total income | 141.12 | 147.27 | −4.2% | 167.11 | −15.6% |
| Profit before tax | (0.04) | (2.12) | Loss narrowed | 4.38 | Turned loss |
| Net profit for the period | (1.99) | (1.99) | Unchanged | 4.44 | Turned loss |
| Attributable to shareholders of the company | (1.89) | (1.43) | Loss widened | 4.52 | Turned loss |
| EPS, basic (₹) | (0.31) | (0.23) | Loss widened | 0.74 | Turned loss |
| Net margin (%) | -1.5 | -1.5 | 2.7 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 67.90 | 80.37 | −15.5% | 108.43 | −37.4% |
| Other income | 6.09 | 16.39 | −62.8% | 3.32 | +83.4% |
| Total income | 73.99 | 96.76 | −23.5% | 111.75 | −33.8% |
| Profit before tax | (22.03) | (1.35) | Loss widened | 9.65 | Turned loss |
| Net profit for the period | (12.39) | (1.37) | Loss widened | 9.65 | Turned loss |
| EPS, basic (₹) | (2.02) | (0.22) | Loss widened | 1.58 | Turned loss |
| Net margin (%) | -18.2 | -1.7 | 8.9 |
Consolidated
- Filed with BSE
- 30 May 2025, 21:53 IST
- Board meeting
- 30 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2025, 21:53 IST
- Board meeting
- 30 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE